Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

Affinium Awarded $4.8M Biodefense Contract

  • Affinium Pharmaceuticals executed a $4.8-million contract with the Defense Threat Reduction Agency (DTRA) to aid its research, which has relevance to potential biological warfare and bioterrorism agent.

    The two-year contract will fund preclinical studies of selected compounds from Affinium's fatty acid biosynthesis inhibitor portfolio that have demonstrated potential as therapeutics for the treatment of diseases caused by serious pathogens including Francisella tularensis.

    Under the contract, Affinium will investigate the properties of a select group of its compounds. Following these initial investigations, the company and its partners will conduct microdosing studies to characterize the compounds' human pharmacokinetic properties and select a lead development candidate to undergo IND-enabling preclinical development as an oral tularemia therapeutic.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »